Founded in 2019 by the venture capital firm Forbion and John Kastelein, NewAmsterdam Pharma is a privately held, clinical-stage company focused on the research and development of transformative therapies for cardiometabolic diseases. Its mission is to improve patient care in populations where traditional therapies are not tolerated or have been unsuccessful.

Biotechnology

New Amsterdam Pharma

Michael Davidson

BJ Jones

Matthew Philippe

Sheng Cui

Jim Jacobson

David Topper

Bob Rambo

Annie Neild

Douglas Kling

Louise Kooij

John Kastelein

Board and Advisory Team

Executive Management Team

Finance Team

Clinical Operations

Leadership Team

Teams at New Amsterdam Pharma

Board and Advisory Team

Executive Management Team

Finance Team

Clinical Operations

Leadership Team